Novo Nordisk, the Danish pharmaceutical company, recently announced its plans to invest 15.9 billion Danish kroner (around $2.3 billion) in expanding its manufacturing capacity for chronic disease medications at a facility located north of Copenhagen . This investment follows previous projects to increase production of clinical trial drugs and ingredients for oral and injectable medications .
The company stated that this expansion will facilitate the ongoing development of late-stage drugs in its pipeline, with the production of drug ingredients slated to begin by early 2029 . The project is expected to create 340 new jobs once the plant is fully operational .
This expansion is intended to support Novo Nordisk’s development of treatments for serious chronic diseases, including diabetes, obesity, non-alcoholic liver disease, Alzheimer’s, hemophilia, sickle cell disease, and heart disease .
